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httpcense.Abstract In themanagement ofCOPDwith respiratory failure two types of non invasive ventilation,
continuous positive airway pressure and bilevel positive airway pressure (CPAP and BIPAP) were
emergedwith the aim of correcting gas exchange abnormalities and avoiding endotracheal intubation.
Aim of the work: To evaluate and compare the effectiveness of 2 types of noninvasive respiratory
support systems, continuous positive airway pressure, and bilevel positive pressure ventilation in
treatment of acute exacerbation of chronic obstructive pulmonary disease:
This study included 60 patients with acute exacerbation of chronic obstructive pulmonary disease
(COPD) (48 males and 12 females) with age ranged from (51 to 69 years) admitted in Chest Depart-
ment and Respiratory Care Unit in Chest Department Sayed Galal University Hospital, Al Azhar
University during the period betweenMay 2011 and February 2012. These patients fulﬁlled the diag-
nostic criteria for COPD patients with acute respiratory failure with exclusion of patients presenting
with any of exclusive criteria for non invasive ventilation.
Patients were classiﬁed randomly into 3 groups.
1. Group 1 (CPAP group): included 20 patients treated with standard therapy plus respiratory sup-
port with CPAP using the apparatus (VPAP III ST-A with QuickNav) and use a Res Med mask.
2. Group 2 (BIPAP group): included 20 patients treatedwith standard therapy plus respiratory sup-
port with CPAP using the apparatus (VPAP III ST-A with QuickNav) and use a Res Med mask.
3. Group 3 (standard group): Included 20 patients treated with controlled oxygen therapy, antibi-
otics, bronchodilators, corticosteroids, anticoagulant and other medications needed for the patient.com (A. Ameen).
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96 A. Ameen et al.All patients were subjected to history taking, clinical examination, routine laboratory investiga-
tions, chest X-ray, ECG and blood gasses analysis.
Results: This study revealed the following:
 Clinical assessment at time of admission revealed non signiﬁcant difference between the three
groups as regard respiratory rate, pulse, systolic and diastolic blood pressure (SBP andDBP) and con-
sciousness level at time of admission with p value 0.767, 0.252, 0.350, 0.441and 0.817 respectively and
there was no statistically signiﬁcant difference between the three groups as regard Pa02, PaC02, 02 sat-
uration and pH with p value 0.127, 0.077, 0.098 and 0.998 respectively.
 In group 2 (BIPAP group):
- There was improvement in the arterial Pa02 in comparison to group 1 and 3 after 1, 6, 12 h and on
second day with signiﬁcant improvement especially after 6, 12 h and in second day with p value
0.013 < 0.001 and 0.012 respectively.
- There was signiﬁcant improvement in the arterial PaCO2 in comparison to group 1 and 3 after 1, 6,
12 h and on second day with p value 0.000, 0.000, 0.012 and 0.002 respectively.
- There was improvement in 02 saturation in comparison to group 1 and 3 after 1, 6, 12 h and on
second day with signiﬁcant improvement especially after 12 h and on second day with p value
0.0492 and 0.041 respectively.
- There was mild improvement in arterial pH in comparison to group 1 and 3 with signiﬁcant
improvement especially after 12 h with p value (0.001).
As regard duration of stay in ICU, there was less duration of stay in both groups 1 and 2 in com-
parison to group 3 with decrease, but non signiﬁcant, in duration of stay in ICU in group 2 in com-
parison to group 1.
Finally group 2 (BIPAP group) had signiﬁcant statistical difference in avoiding endotracheal intu-
bation ETI in comparison to group 1 and 3 with p value (0.033).
Conclusion: BIPAP has a superior efﬁcacy in correcting gas exchange abnormalities and avoiding
endotracheal intubation than CPAP.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
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Noninvasive positive-pressure ventilation (NPPV) has been
used increasingly to treat acute respiratory failure (ARF).
The best indications for its use are ARF in patients with
COPD exacerbations, acute pulmonary edema, and immuno-
compromised states [1].
Two noninvasive methods for applying positive respiratory
pressure exist as follows: by mask with continuous positive
pressure in the airways (continuous positive airway pressure)
or by ventilation with 2 levels of pressure (bilevel positive pres-
sure ventilation) [2]. In the case of continuous positive airway
pressure, the predetermined value of pressure remains constant
during the entire respiratory cycle, and the respiratory work is
completely performed by the patient. During bilevel pressure
ventilation, the pressure is higher during inspiration and de-
creases during expiration. It is a modality that supports inspi-
ration and, therefore, directly reduces the patient’s respiratory
work. Even though evidence exists in the literature about the
advantages of the use of the face mask with positive pressure
in the airways for treating patients with acute cardiogenic pul-
monary edema, doubts about the best ventilatory modality
persist, because most studies have been limited to analyzing
the effects of using this method [3].
CPAP, BIPAP and other non-invasive ventilation modes
have been shown to be effective management tools for chronic
obstructive pulmonary disease and acute respiratory failure [4].
Bilevel positive airway pressure is used when positive air-
way pressure is needed with the addition of pressure support.
Common situations where positive airway pressure is indicatedis any disease where taking a breath is difﬁcult. This includes
pneumonia, chronic obstructive pulmonary disease, asthma
and status asthmaticus in children [5,6].
Biphasic/bilevel as a mode of ventilation was ﬁrst presented
in 1988 by Professor Benzer of Innsbruck and his group. His
theory consisted of alternating PEEP levels [7]. This was the
ﬁrst time the acronym BIPAP was used and was followed in
1989 with the publication of a new approach to ventilatory
technique [8] by Baum & Benzer which was also the ﬁrst full
year of commercial introduction of ‘‘Biphasic Positive Airway
Pressure’’ as an integrated mode of ventilation on the Evita
ventilator. This concept was introduced as a positive adjunct
to weaning from ventilator support.
Aim of the work
To evaluate and compare the effectiveness of 2 types of noninva-
sive respiratory support systems, continuous positive airway
pressure, and bilevel positive pressure ventilation in treatment
of acute exacerbation of chronic obstructive pulmonary disease:
Patients and methods
1-Patients
This study included 60 patients with acute exacerbation of
chronic obstructive pulmonary disease (COPD) admitted in
Chest Department and Respiratory Care Unit in Chest
Department Sayed Galal University Hospital, Al-Azhar Uni-
versity during the period between May 2011 and February
2012 .
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1. History of COPD conﬁrmed by clinical examinations
and chest radiography.
2. Type II respiratory failure due to acute exacerbations
of COPD evident by clinical and laboratory ﬁndings
include worsening of symptoms and tachypnea respira-
tory rate >30/min,PaO2 < 60 mmHg, PaCO2 > 50
mmHg, pH < 7.35, serum HCO3 normal or elevated,
a normal level of consciousness or moderate signs of
respiratory encephalopathy (drowsiness, confusion,
and ﬂapping tremors).
3. Clinical assessment of consciousness level was
expressed as (0), normal, (1), mild asterixis, (2), marked
asterixis, mild confusion, or sleepiness during the day,
(3), major confusion with day time sleepiness or agita-
tion, 0 (4), major agitation.
Exclusion criteria
Patients were excluded from this study if they had any of the
following:
- Indication for endotracheal intubation.
- Hypotension deﬁned as systolic blood pressure <90 mmHg
and diastolic blood pressure <60 mmHg.
- Presence of ventricular or atrial arrhythmia.
- Inability to cooperate with the ﬁtting and wearing of the
face mask.
- Presence of upper airway obstruction or facial trauma or
presence of tracheostomy.
II-Methods
All the patients were subjected to the following: History tak-
ing, clinical examination, plain X-ray chest, ECG, and arterial
blood gasses analysis on admission and after 1, 6, 12 h and on
second day.
Patients were classiﬁed into 3 groups:
1. Group 1 (CPAP group):included 20 patients treated with
standard therapy plus respiratory support with CPAP using
the apparatus (VPAP III ST-A with QuickNav) and use a
Res Med mask.
2. Group 2 (BIPAP group): included 20 patients treated with
standard therapy plus respiratory support with BIPAP
using the apparatus (VPAP III ST-A with QuickNav) and
use a ResMed mask.
3. Group 3 (standard group): Included 20 patients treated
with controlled oxygen therapy, antibiotics, bronchodila-
tors, corticosteroids, anticoagulants and other medications
needed for the patients.Table 1 Sex distribution among studied cases.
Sex Group I Group II G
N % N % N
Female 4 20 5 25 3
Male 16 80 15 75 1Monitoring of the patients during study- Clinical observation for consciousness level,arterial blood
pressure, arterial blood gasses presetting, and after 1, 6,
and 12 h, and on second day.
Invasive mechanical ventilation was initiated for any pa-
tient who developed criteria necessitating invasive mechanical
ventilation.
Weaning from CPAP or BI PAP
The patient was weaned from non invasive ventilatoy support
when the patient fulﬁlled the criteria for separation which were





This study included 60 patients with acute exacerbation of
chronic obstructive pulmonary disease (COPD) (48 males and
12 females)with age ranging from (51–69 years) admitted to
Chest Department and Respiratory Care Unit in Chest Depart-
ment, Sayed Galal University Hospital, Al Azhar University
during the period between May 2011 and February 2012.
These patients were randomly classiﬁed into 3 groups.
- Group (1) CPAP group;
- Group (2) BIPAP group;
- Group (3) standard group.
There was no statistically signiﬁcant difference between pa-
tients of the three groups as regard sex (p value 0.732) and age
(p value 0.621) Tables 1 and 2.
Clinical assessment for the patients of all groups at time of
admission, Table 3, revealed no statistically signiﬁcant differ-
ence as regard respiratory rate, pulse, systolic and diastolic
blood pressure (SBP and DBP) and conscious level with p va-
lue (0.767, 0.252, 0.350, 0.441 and 0.317) respectively.
Assessment of arterial blood gasses at time of admission
Table 4 revealed that there was no statistically signiﬁcant dif-
ference between patients of the three groups as regard PaO2,
PaCO2, O2 saturation and pH with p value (0.127, 0.077.
0.098 and 0.998) respectively.
In this study there was improvement in PaO2 in patients of
group 2 (BIPAP group) during the follow up period after 1, 6,
12 h and on second day, Table 5 with statistically signiﬁcant
improvement after 6 and 12 h and on second day with p valueroup III Total Chi-square
% N % X2 p-value
15 12 20 0.625 0.732
7 85 48 80
Table 2 Age distribution among studied cases.
Age ANOVA
Range Mean ± SD f p-value
Group I 51.000–67.000 59.350 ± 3.843 0.481 0.621
Group II 50.000–69.000 58.500 ± 5.520
Group III 54.000–68.000 59.850 ± 3.588
98 A. Ameen et al.(0.013, 0.001 and 0.012) respectively. These results are in agree-
ment with Strumpf et al. [9] who studied the effect of nocturnal
positive pressure ventilation BIPAP via nasal mask in patients
with severe chronic obstructive pulmonary disease.Table 4 Comparison between the three groups as regard arterial b
At admission Group I (CPAP) Group II
Mean ± SD Mean ± SD
PaO2 50.400 ± 1.789 50.600 ± 7.366
PaCO2 66.650 ± 5.480 69.900 ± 4.241
O2 sat 79.450 ± 2.800 77.150 ± 3.100
pH 7.266 ± 0.034 7.267 ± 0.153
Table 5 Comparison between the three groups as regard PaO2 afte
PaO2 Group I (CPAP) Group II (BIPAP) Group II
Mean ± SD Mean ± SD Mean ±
After 1 h 56.450 ± 3.017 54.900 ± 4.553 56.650 ±
After 6 h. 58.750 ± 6.851 62.750 ± 6.223 58.550 ±
After 12 h. 63.300 ± 8.927 66.100 ± 7.305 60.900 ±
Second day 68.500 ± 11.936 73.750 ± 10.809 66.150 ±
Table 3 Clinical assessment at time of admission.
Range
RRa Group I 31.000–38.0
Group II 31.000–39.0
Group III 31.000–39.0
Pulse Group I 105.000–130
Group II 100.000–130
Group III 97.000–127.
SBPb Group I 100–140
Group II 110–130
Group III 100–140
DBPc Group I 70–90
Group II 70–85
Group III 65–90
Conscious level at admission Group I 0–2
Group II 0–2
Group III 0–2
a RR, respiratory rate.
b SBP, systolic blood pressure.
c DBP, diastolic blood pressure.In this study there was signiﬁcant improvement in PaCO2 in
patients of group 2 (Bipap group) after 1, 6, 12 h and on sec-
ond day in comparison to group [1] (CPAP group) and group
[3] (standard group), Table 6. These results are in accordance
with those reported by Casanova et al. [10], who studied the
effect of nocturnal nasal positive pressure ventilation in pa-
tients with severe COPD, and Krachman et al. [11], who eval-
uated the effect of non invasive BIPAP ventilation on gas
exchange and sleep in COPD patients.
Clini et al. [12] evaluated the effect of early use of noninva-
sive ventilation on gas exchange in patients with acute exacer-
bation of COPD and concluded that reduction of hypercapnia
was greater in patients who received BIPAP ventilation. Also
Strumpf et al. [9] found that the reduction of hypercapnialood gasses at time of admission.
Group III ANOVA
Mean ± SD f p-value
52.600 ± 2.909 1.653 0.127
68.350 ± 7.909 1.091 0.077
78450 ± 2.438 1.876 0.098
7.268 ± 0.031 0.002 0.998
r 1, 6, 12 h and on second day.
I ANOVA Tukey’s test
SD F p-value I & II I & III II & III
4.082 1.184 0.313 0.178 0.732 0.114
5.799 3.208 0.013 0.002 0.802 0.003
6.257 5.966 <0.001* 0.000 0.062 0.000
9.167 3.382 0.012* 0.000 0.030 0.000
Mean ± SD ANOVA
f p-value
00 34.800 ± 2.142 0.267 0.767
00 34.250 ± 2.268
00 34.550 ± 2.704
.000 116.700 ± 8.170 1.41 0.252
.000 119.300 ± 8.892
000 114.500 ± 9.971
125.55 ± 12.57 1.222 0.350
122.75 ± 13.49
124.48 ± 15.35
80.22 ± 5.87 1.135 0.441
82.75 ± 6.85
80.77 ± 5.71
1.05 ± 0.76 0.203 0.817
1.00 ± 0.79
0.90 ± 0.72
Table 6 Comparison between the three groups as regard PaCO2 after 1, 6, 12 h and on second day.
PaCO2 Group I (CPAP) Group II (BIPAP) Group III ANOVA Tukey’s test
Mean ± SD Mean ± SD Mean ± SD F p-value I & II I & III II & III
After 1 h 63.450 ± 5.073 65.900 ± 3.177 70.450 ± 6.013 10.517 0.000 0.262 0.000 0.013
After 6 h 59.200 ± 3.968 57.600 ± 4.185 67.000 ± 5.047 25.837 0.000 0.492 0.000 0.000
After 12 h. 54.050 ± 3.663 51.950 ± 4.236 55.050 ± 3.873 3.479 0.012 0.000 0.802 0.252
Second day 50.200 ± 5.979 46.350 ± 4.804 49.500 ± 4.947 4.128 0.002 0.000 0.907 0.170
Table 7 Comparison between the three groups as regard O2 sat after 1, 6, 12 h and on second day.
O2 sat Group I (CPAP) Group II (BIPAP) Group III ANOVA Tukey’s test
Mean ± SD Mean ± SD Mean ± SD F p-value I & II I & III II & III
After 1 h. 81.050 ± 2.373 77.950 ± 2.012 83.000 ± 2.271 26.229 0.000 0.000 0.020 0.000
After 6 h. 83.000 ± 2.152 82.150 ± 2.889 82.450 ± 1.761 0.693 0.504 0.481 0.734 0.912
After 12 h. 84.200 ± 1.824 88.350 ± 5.383 83.600 ± 2.326 2.258 0.0492 0.044 0.854 0.271
Second day 87.900 ± 7.181 91.450 ± 5.558 89.000 ± 4.472 3.177 0.041 0.040 0.823 0.952
Table 8 Comparison between the three groups as regard pH after 1, 6, 12 h and on second day.
PH Group I(CPAP) Group II(BIPAP) Group III ANOVA Tukey’s test
Mean ± SD Mean ± SD Mean ± SD F p-value I & II I & III II & III
After 1 h. 7.288 ± 0.027 7.273 ± 0.036 7.278 ± 0.032 1.218 0.304 0.281 0.584 0.849
After 6 h. 7.304 ± 0.025 7.299 ± 0.016 7.300 ± 0.024 0.311 0.734 0.755 0.796 0.997
After 12 h. 7.289 ± 0.047 7.348 ± 0.059 7.307 ± 0.028 8.481 0.001 0.001 0.458 0.021
Second day 7.351 ± 0.071 7.377 ± 0.048 7.351 ± 0.079 1.037 0.361 0.431 1.000 0.431
Table 9 Comparison between three groups in relation to duration of stay in ICU.
Duration Range Mean ± SD ANOVA Tukey’s test
f p-value p-value
Group I 3.000–6.000 4.154 ± 0.987 3.568 0.037 I & II 0.954
Group II 2.000–7.000 4.300 ± 1.809 I & III 0.054
Group III 4.000–7.000 5.500 ± 0.905 II & III 0.061
Table 10 Comparison between complications in CPAP (group I) and BIPAP (group II).
Complications Group I (CPAP) Group II (BIPAP) Chi-square
N % N % X2 p-value
Skin irritation 4 20.00 3 15.00 0.536 0.765
Eye irritation 4 20.00 2 10.00
Uncooperation 6 30.00 2 10.00
Comparison between continuous positive airway pressure and bilevel positive pressure ventilation 99noted on continuous nocturnal monitoring of end- tidal car-
bon dioxide tension and PaCO2 is greater than that observed
by Meecham Jones et al. [13] who studied the effect of nasal
pressure support ventilation plus oxygen compared with oxy-
gen therapy alone in hypercapnic COPD. The extent of re-
duced hypercapnia which was greater in comparison with the
study done by Meecham Jones et al. [13] suggesting that theeffectiveness of bilevel NIPPV is greater in COPD patients
with a higher baseline PaCO2. Nocturnal PaCO2 monitoring
may be a more dynamic measure of effectiveness of bilevel
NIPPV in reduction of hypercapnia in patients with severe sta-
ble COPD than arterial blood gasses alone.
In this study there was improvement in O2 saturation in pa-
tients of group 2 (BIPAP group), Table 7, during the follow up
Table 11 Comparison between group I and group II as regard success rate.
Succeeded Group I (CPAP) Group II (BIPAP) Group III Chi-square
N % N % N % X2 p-value
S 11 55 18 90 8 40 4.514 0.033*
F 9 45 2 10 12 60
100 A. Ameen et al.period after 1, 6, 12 h and on second day with statistically sig-
niﬁcant improvement after 12 h and in second day (p value
0.0492 and 0.041).
Comparing group 1 (CPAP group) to group 2 (BIPAP
group) using Tukey’s test, revealed that group 1 showed im-
proved O2 saturation in ﬁrst hour and after 6 h, this may be
explained by intolerance to the use of BIPAP. by the time,
O2 saturation have been signiﬁcantly improved after 12 h
and on second day.
In this study there was mild improvement in arterial pH in
patients of group 2 (BIPAP group), Table 8, in comparison to
group 1 after 1, 6 h and on second day with signiﬁcant
improvement after 12 h (p value 0.001). These results are in
agree with Plant et al. [14] who found more rapid improvement
in arterial PH, respiratory rate and breathlessness in the NIP-
PV group compared to the control group however, the mortal-
ity beneﬁt was not apparent in patients with a pH < 7.3.
In this study it was found that the duration of ICU stay,
Table 9, was signiﬁcantly shorter in patients of group 1 and
2 in comparison to group 3 with less, but non signiﬁcant, de-
crease in duration of ICU stay in group 2 in comparison to
group 1. These results are in accordance with those reported
by Brochard et al. [15] who showed that pressure support ven-
tilation administered via a face mask signiﬁcantly reduced the
need for intubation, the duration of mechanical ventilation
and ICU length of stay. A more recent study by Kolodzie
et al. [16] reported that the use of bilevel noninvasive positive
pressure ventilation (NIPPV) in acute respiratory failure due
to COPD exacerbation has been shown to reduce the need
for intubation and mechanical ventilation, the length of hospi-
tal stay, and mortality.
In this study comparison between complications in group 1
(CPAP group) and group 2 (BIPAP group), Table 10, showed
no signiﬁcant difference between the two groups (p value
0.765). These results are in accordance with Lin [17] who re-
ported that the most prevalent complaints were related to
asynchrony and sleep.
Also kolodzie et al. [16] reported that the most prevalent
complaints were related to asynchrony and sleep, inability to
tolerate pressure-level settings, dry nose and/or mouth or
mask/interface intolerance due to problems such as leak or na-
sal skin lesions. Two studies reported bilevel NIPPV intoler-
ance with no reasons cited [18].
In this study it was found that there was a signiﬁcant de-
crease in the rate of ETI among patients of group 2 (BIPAP
group) (20%) compared to group 1 (45%) and group 3
(60%) as shown in Table 11 with p value (0.033). These results
are in agreement with the large multi center Europian trial
conducted by Lightowler et al. [19] which showed that COPD
patients with acute exacerbation who randomized to NIPPV
had signiﬁcantly lower ETI rate than conventionally treated
patients (26% versus 74%) respectively.References
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